Charles Schwab Investment Management Inc. Boosts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Charles Schwab Investment Management Inc. increased its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 17.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 187,165 shares of the company’s stock after buying an additional 27,628 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Takeda Pharmaceutical were worth $2,661,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Millennium Management LLC boosted its stake in Takeda Pharmaceutical by 87.1% during the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after purchasing an additional 2,023,707 shares during the last quarter. Van ECK Associates Corp boosted its stake in Takeda Pharmaceutical by 6.6% during the 3rd quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after purchasing an additional 134,407 shares during the last quarter. Cowen AND Company LLC purchased a new stake in Takeda Pharmaceutical during the 2nd quarter valued at $6,866,000. Pathstone Holdings LLC lifted its holdings in shares of Takeda Pharmaceutical by 1.0% during the 3rd quarter. Pathstone Holdings LLC now owns 430,676 shares of the company’s stock valued at $6,124,000 after buying an additional 4,280 shares during the period. Finally, Summit Global Investments lifted its holdings in shares of Takeda Pharmaceutical by 86.0% during the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after buying an additional 192,143 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $13.42 on Monday. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The stock’s fifty day moving average is $13.81 and its 200 day moving average is $13.89. The stock has a market cap of $42.70 billion, a P/E ratio of 23.14, a P/E/G ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.